Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.41 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955091 | 0.87 | FFAR1 (0.49) | HPGDNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL956573 | 0.76 | FFAR1 (0.50) | LMNARAB9A | |
| SCHEMBL956425 | 0.72 | KDM4E (0.39) | NPC1DPP4SMN1; SMN2 | |
| SCHEMBL956589 | 0.72 | FFAR1 (0.37) | — | |
| SCHEMBL3344200 | 0.72 | MAPT (0.43) | NPC1DPP4RAB9ASMN1; SMN2 | |
| SCHEMBL3339372 | 0.71 | PTGDR2 (0.40) | NPC1DPP4RAB9ASMN1; SMN2 | |
| SCHEMBL8288272 | 0.71 | MRGPRX4 (0.64) | MRGPRX4HPGDNPC1S1PR4LMNA | |
| SCHEMBL12098175 | 0.67 | ALDH1A1 (0.49) | MRGPRX4HPGDNPC1S1PR4LMNA | |
| SCHEMBL22480484 | 0.67 | MRGPRX4 (1.00) | MRGPRX4S1PR4 | |
| SCHEMBL3338701 | 0.66 | CXCR2 (0.40) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2257552-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009106539-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR3 | MRGPRX4 37/4885HPGD 488/4885NPC1 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.